P. Lei

Integrative Omics Uncovers Low Tumorous Magnesium Content as A Driver Factor of Colorectal Cancer

This study identifies low tumorous magnesium content as a driver factor of colorectal cancer by showing its impact on gene mutations, EMT activation, and cell migration through DBN1 phosphorylation.

Combined blockade of CXCR4 and PD-1 enhances intratumoral dendritic cell activation and immune responses against HCC

This study shows that blocking CXCR4 and PD-1 together improves dendritic cell activation and immune responses against HCC in mouse models.

Losartan rewires ovarian cancer tumor-immune microenvironment and suppresses IGF-1 to amplify chemo-immunotherapy sensitivity

This study shows losartan improves chemo-immunotherapy effectiveness in ovarian cancer by altering the tumor microenvironment and reducing IGF-1 signaling in cancer cells.

Combined blockade of VEGF, Angiopoietin-2, and PD1 reprograms glioblastoma endothelial cells into quasi-antigen-presenting cells

This study shows that blocking VEGF, Ang2, and PD1 reprograms GBM endothelial cells into quasi-antigen-presenting cells, enhancing anti-tumor responses and controlling edema.

A multispecific antibody prevents immune escape and confers pan-SARS-CoV-2 neutralization

This paper develops multispecific antibodies that neutralize all SARS-CoV-2 variants, including Omicron, by targeting multiple epitopes on the spike protein.

IFNA pathway drives the more aggressive phenotype of KRASG12D-mutant pancreatic ductal adenocarcinomas via IFNAR1/STAT3 activation

The paper shows that the IFNA pathway promotes aggressive KRASG12D-mutant pancreatic ductal adenocarcinomas through IFNAR1/STAT3 activation and identifies IFNAR1 inhibition as a potential therapeutic strategy.

Close homologue of L1 sensitizes lung cancer cells to cisplatin and paclitaxel via inhibition Akt pathway

This study shows that CHL1 overexpression reverses chemoresistance to cisplatin and paclitaxel in lung cancer by inhibiting the Akt pathway.